Tag: NYSEMKT:INO

  • Small Cap Advancers: Yingli Green Energy Hold (NYSE:YGE), Galena Biopharma Inc (NASDAQ:GALE), Arena Pharmaceuticals (NASDAQ:ARNA), Inovio Pharmaceuticals (NYSEMKT:INO)

    Yingli Green Energy Hold. Co. Ltd. (ADR) (NYSE:YGE) Australia has entered into a distribution agreement with Energy Matters, an Australia solar supply and installation company. Energy Matters will supply and install Yingli Solar’s monocrystalline PANDA Series modules and multicrystalline YGE Series modules to homes and businesses. Yingli Green Energy Hold. Co. Ltd. (ADR) (NYSE:YGE) stock opened at $5.50 in last trading session, and closed at $5.96, trading in the range of $5.48 – $5.98. The stock showed a positive weekly performance of 4.20%.

    TheStreet Quant Ratings rates Galena Biopharma Inc (NASDAQ:GALE) as a sell. The company’s weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share . Galena Biopharma Inc (NASDAQ:GALE) shares closed at $5.39 on last trade day, by gaining 9.33%. Stock 52 week range is $1.65 – $7.77. Company’s market capitalization is $567.22 billion.

    Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported that Eisai has secured improved patient access of BELVIQ® (lorcaserin HCl) with two leading healthcare benefit companies, and that the estimated number of insured commercial lives in the United States that have coverage for BELVIQ now exceeds 50 percent. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock advanced 7.17% and finished the last session at $6.43. The EPS of the stock remained -0.08. Company’s market capitalization is $1.41 billion.

    Inovio Pharmaceuticals Inc (NYSEMKT:INO) announced today that it has been invited by the New York Stock Exchange to ring the Opening Bell® tomorrow, February 12th, to mark the beginning of an exciting year for the company in which it will reveal all-important phase II efficacy and immune response data for its lead cancer immunotherapy; continue to advance its prostate cancer and hepatitis B therapies in partnership with Roche; and initiate several new clinical trials for cancer immunotherapies. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock opened at $2.60 in last trading session and closed at $2.73. The 52 week range of the stock is $0.49 – $3.03 and the day range was $2.58 – $2.78.